Dermapharm Holding Se · XETR:DMP
Dermapharm — FY2018 Earnings Presentation
22 slides from Dermapharm's earnings presentation, Apr 17, 2019
Slide 1: Investor and Analyst Conference Call FY 2018
Investor and Analyst Conference Call FY 2018 Grünwald, April 17, 2019
Slide 2: Agenda
Agenda 1. Overview 2. Financial figures FY 2018 3. Outlook FY 2019
Slide 3: Agenda
Agenda 1. Overview 2. Financial figures FY 2018 3. Outlook FY 2019
Slide 4: Dermapharm – Pharmaceutical excellence “Made in Germany”
Dermapharm – Pharmaceutical excellence “Made in Germany” A leading German pharmaceutical company… …based on an integrated business model… ▪ Dermapharm is a leader in branded pharmaceuticals in selected markets in Germany and has an increasing international footprint ▪ Flexible pharmaceutical manufac
Slide 5: Steady organic revenue growth supported by M&A activities
Steady organic revenue growth supported by M&A activities – with strongly increasing direct payer share Revenue by market access excl. axicorp(1) Comments ▪ Acquisitions of Trommsdorff, Strathmann and the hyperthermic devices further strengthen portfolio 5% shift in 2018 36% FY 2018 37% 27% 21% 58%
Slide 6: Highlights FY 2018 – Success story with profitable growth continued
Highlights FY 2018 – Success story with profitable growth continued Continued significant revenue growth with further improved profitability Revenues up 22.5% to € 572.4 million, adjusted EBITDA(1) up 27.0% to € 143.4 million, 1 adjusted EBITDA margin of 25.1% Significant growth impulses from Brande
Slide 7: Agenda
Agenda 1. Overview 2. Financial figures FY 2018 3. Outlook FY 2019
Slide 8: Dermapharm Group Revenue – Driven by significant growth in Branded Pharmaceuticals segment
Dermapharm Group Revenue – Driven by significant growth in Branded Pharmaceuticals segment Dermapharm’s revenue development Dermapharm Group FY 2017 vs FY 2018 €m, YoY growth (%) ▪ Strong revenue growth of 22.5% to € 572.4 million ▪ Main growth drivers: ▪ Successful company acquisitions and integrat
Slide 9: Dermapharm Group EBITDA – Disproportional EBITDA growth
Dermapharm Group EBITDA – Disproportional EBITDA growth Dermapharm’s EBITDA(1) development Dermapharm Group FY 2017 vs FY 2018 €m, YoY growth (%) ▪ EBITDA growth driven by Branded pharmaceuticals EBITDA margin ▪ One-time costs of € 1.4 million for IPO preparations excl. axicorp 46.7% 39.7% ▪ One-tim
Slide 10: Earnings before tax (EBT) – Reflecting company’s high profitability
Earnings before tax (EBT) – Reflecting company’s high profitability Dermapharm’s EBT(1) development Comments FY 2017 vs FY 2018 €m, YoY growth (%) ▪ EBT increased by 18.4% to € 104.2 million (unadjusted) resulting in a margin of 18.2% Group EBT margin 18.8% 18.2% ▪ Depreciations and amortization at
Slide 11: Strong Cash flows and cash conversion
Strong Cash flows and cash conversion – Reflecting strong dedication to future growth Strong cash flow and cash conversion(1) Comments in €m / in % of group EBITDA ▪ CF from operating activities up due to positive business development Cash 78.8% 110.9% conversion ▪ CF from investing activities mainl
Slide 12: Balance sheet of Dermapharm Group
Balance sheet of Dermapharm Group Balance Sheet as of 31 December 2018 Comments in €m ▪ Total assets increased to € 704.6 million 704.6 704.6 ▪ Non-current assets increased mainly due to the increase in intangible assets, Goodwill and Property, plant and equipment Equity 256.1 Non-current 333.3 asse
Slide 13: Agenda
Agenda 1. Overview 2. Financial figures FY 2018 3. Outlook FY 2019
Slide 14: Growth strategy – Update on in-house development
Growth strategy – Update on in-house development FY 2018 2019 Achievements Plans ▪ All ongoing development projects on track ▪ ~ 50 ongoing development projects with new products for all ▪ Several new products launched in different countries product areas ▪ Germany: Myopridin®, Summavit® materna, Si
Slide 15: Growth strategy – Update on internationalization
Growth strategy – Update on internationalization FY 2018 2019 Achievements Plans ▪ First marketing authorizations for subsidiaries in the UK ▪ Launch of first products in UK and Italy and Italy ▪ Entering Spain via Euromed ▪ Marketing authorizations obtained in EU for several of ▪ Continuous screeni
Slide 16: Growth strategy – Update on M&A activities
Growth strategy – Update on M&A activities FY 2018 2019 Achievements Plans ▪ Integration and consolidation of Strathmann, Trommsdorff, ▪ Scheduled continuation of the integration of Bio-Diät-Berlin, Bio-Diät-Berlin and Hyperthermic Medical Devices further Strathmann and Trommsdorff: strengthen overa
Slide 17: Growth strategy – Expansion of production and logistics capacities
Growth strategy – Expansion of production and logistics capacities FY 2018 2019 Achievements Plans mibe GmbH Arzneimittel in Brehna (Germany) ‒ Construction of a new central logistics building ▪ Start of the construction project realized in September 2018 ▪ Completion of the project until September
Slide 18: Business update on axicorp Group
Business update on axicorp Group FY 2018 2019 Achievements Plans ▪ Reduction of purchase prices ▪ Ongoing portfolio optimization ▪ Further broadening of sourcing ▪ Adaptation of business to new legal frame conditions ▪ Further leverage of the call center ▪ Preparation of Cannabis – sales activities
Slide 19: Growth strategy on track and informing guidance 2019
Growth strategy on track and informing guidance 2019 EBITDA Revenues +14% to +19% 2019 +17% to +22% 2019 (adjusted) ▪ over previous year (2018: € 572 million) ▪ over previous year (2018: € 143.4 million (adjusted)) “Growth rates are based on organic growth, new launches of in-house developments and
Slide 20: Disclaimer
Disclaimer This publication includes statements, estimates, opinions and projections with respect to the anticipated future performance of Dermapharm Holding SE (together with its consolidated subsidiaries, “Dermapharm”) and such statements, estimates, opinions and projections (“Forward-Looking Stat
Slide 21: Investor contact
Investor contact Britta Hamberger Investor Relations Dermapharm Holding SE E-Mail: ir@dermapharm.com Phone: +49 (0) 89 641 86 233
Slide 22: Becoming the leading European pharmaceuticals manufacturer in selected markets
Becoming the leading European pharmaceuticals manufacturer in selected markets